Cover Image
市場調查報告書

Respiratorius AB - 產品平台分析

Respiratorius AB - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 219746
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Respiratorius AB - 產品平台分析 Respiratorius AB - Product Pipeline Review - 2015
出版日期: 2015年12月23日 內容資訊: 英文 23 Pages
簡介

Respiratorius AB 開發癌症和慢性阻塞性肺病,氣喘等藥物候補的製藥公司。同時也開發生物標記和心血管PET影像設備。

本報告提供Respiratorius AB的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Respiratorius AB的基本資料

Respiratorius AB概要

  • 主要資訊
  • 企業資料

Respiratorius AB:R&D概要

  • 主要的治療範圍

Respiratorius AB:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Respiratorius AB:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Respiratorius AB:藥物簡介

  • valproate sodium
  • RESP-1000
  • RESP-2000
  • RESP-1100
  • RESP-1200
  • RESP-2100
  • RESP-2200

Respiratorius AB:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Respiratorius AB:最近的開發平台趨勢

Respiratorius AB:暫停中的計劃

Respiratorius AB:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07914CDB

Summary

Global Markets Direct's, 'Generex Biotechnology Corporation - Product Pipeline Review - 2015', provides an overview of the Generex Biotechnology Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Generex Biotechnology Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Generex Biotechnology Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Generex Biotechnology Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Generex Biotechnology Corporation's pipeline products

Reasons to buy

  • Evaluate Generex Biotechnology Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Generex Biotechnology Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Generex Biotechnology Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Generex Biotechnology Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Generex Biotechnology Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Generex Biotechnology Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Respiratorius AB Snapshot
    • Respiratorius AB Overview
    • Key Information
    • Key Facts
  • Respiratorius AB - Research and Development Overview
    • Key Therapeutic Areas
  • Respiratorius AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Respiratorius AB - Pipeline Products Glance
    • Respiratorius AB - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase 0 Products/Combination Treatment Modalities
    • Respiratorius AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Respiratorius AB - Drug Profiles
    • valproate sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RESP-1000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RESP-2000
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Respiratorius AB - Pipeline Analysis
    • Respiratorius AB - Pipeline Products by Target
    • Respiratorius AB - Pipeline Products by Route of Administration
    • Respiratorius AB - Pipeline Products by Molecule Type
    • Respiratorius AB - Pipeline Products by Mechanism of Action
  • Respiratorius AB - Recent Pipeline Updates
  • Respiratorius AB - Dormant Projects
  • Respiratorius AB - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Respiratorius AB, Key Information
  • Respiratorius AB, Key Facts
  • Respiratorius AB - Pipeline by Indication, 2015
  • Respiratorius AB - Pipeline by Stage of Development, 2015
  • Respiratorius AB - Monotherapy Products in Pipeline, 2015
  • Respiratorius AB - Phase II, 2015
  • Respiratorius AB - Phase 0, 2015
  • Respiratorius AB - Preclinical, 2015
  • Respiratorius AB - Pipeline by Target, 2015
  • Respiratorius AB - Pipeline by Route of Administration, 2015
  • Respiratorius AB - Pipeline by Molecule Type, 2015
  • Respiratorius AB - Pipeline Products by Mechanism of Action, 2015
  • Respiratorius AB - Recent Pipeline Updates, 2015
  • Respiratorius AB - Dormant Developmental Projects,2015
  • Respiratorius AB, Subsidiaries

List of Figures

  • Respiratorius AB - Pipeline by Top 10 Indication, 2015
  • Respiratorius AB - Pipeline by Stage of Development, 2015
  • Respiratorius AB - Monotherapy Products in Pipeline, 2015
  • Respiratorius AB - Pipeline by Top 10 Target, 2015
  • Respiratorius AB - Pipeline by Top 10 Route of Administration, 2015
  • Respiratorius AB - Pipeline by Top 10 Molecule Type, 2015
  • Respiratorius AB - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top